BR112022000397A2 - Imuno-direcionamento não viral - Google Patents

Imuno-direcionamento não viral

Info

Publication number
BR112022000397A2
BR112022000397A2 BR112022000397A BR112022000397A BR112022000397A2 BR 112022000397 A2 BR112022000397 A2 BR 112022000397A2 BR 112022000397 A BR112022000397 A BR 112022000397A BR 112022000397 A BR112022000397 A BR 112022000397A BR 112022000397 A2 BR112022000397 A2 BR 112022000397A2
Authority
BR
Brazil
Prior art keywords
payload
immunotargeting
viral
compositions
disease
Prior art date
Application number
BR112022000397A
Other languages
English (en)
Other versions
BR112022000397A8 (pt
Inventor
P Whitehead Nicholas
C Froehner Stanley
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BR112022000397A2 publication Critical patent/BR112022000397A2/pt
Publication of BR112022000397A8 publication Critical patent/BR112022000397A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1719—Muscle proteins, e.g. myosin or actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

imuno-direcionamento não viral. a revelação fornece composições e métodos para a liberação de uma carga útil às células ou tecidos que expressam glut4. em algumas modalidades, as composições compreendem um anticorpo, ou fragmento ou derivado deste, que se liga especificamente à proteína transportadora de glicose 4 (glut4), e uma carga útil terapêutica conjugada a ela. em algumas modalidades exemplares, as composições são úteis para métodos de tratamento de uma doença ou condição em um indivíduo com uma mutação genética em um gene que codifica proteína distrofina, em que a carga útil compreende um ácido nucleico que codifica uma proteína distrofina funcional ou fragmento funcional desta, para melhorar aspectos da doença.
BR112022000397A 2019-07-10 2020-07-09 Imuno-direcionamento não viral BR112022000397A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872425P 2019-07-10 2019-07-10
PCT/US2020/041441 WO2021007453A2 (en) 2019-07-10 2020-07-09 Non-viral immuno-targeting

Publications (2)

Publication Number Publication Date
BR112022000397A2 true BR112022000397A2 (pt) 2022-04-19
BR112022000397A8 BR112022000397A8 (pt) 2023-02-28

Family

ID=74115289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000397A BR112022000397A8 (pt) 2019-07-10 2020-07-09 Imuno-direcionamento não viral

Country Status (11)

Country Link
US (1) US20220280652A1 (pt)
EP (1) EP3997109A4 (pt)
JP (1) JP2022540819A (pt)
KR (1) KR20220032595A (pt)
CN (1) CN114174322A (pt)
AU (1) AU2020311399A1 (pt)
BR (1) BR112022000397A8 (pt)
CA (1) CA3145992A1 (pt)
CL (1) CL2021003444A1 (pt)
IL (1) IL289624A (pt)
WO (1) WO2021007453A2 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729655B2 (en) * 1996-11-12 2001-02-08 Regents Of The University Of California, The Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
CN1339491A (zh) * 2000-08-23 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人葡萄糖转运蛋白26.62和编码这种多肽的多核苷酸
JP5575486B2 (ja) * 2007-01-18 2014-08-20 ユニヴァーシティ オブ ミズーリー−コロンビア 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子
US8993633B2 (en) * 2009-05-18 2015-03-31 Fate Therapeutics, (Canada) Inc. Treatment of muscle disease characterized by insulin resistance
WO2014055415A1 (en) * 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
MX2020005860A (es) * 2017-12-06 2020-09-09 Avidity Biosciences Inc Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.

Also Published As

Publication number Publication date
CL2021003444A1 (es) 2023-05-05
EP3997109A4 (en) 2023-11-01
CN114174322A (zh) 2022-03-11
IL289624A (en) 2022-03-01
WO2021007453A8 (en) 2021-09-23
AU2020311399A1 (en) 2022-02-17
JP2022540819A (ja) 2022-09-20
BR112022000397A8 (pt) 2023-02-28
KR20220032595A (ko) 2022-03-15
WO2021007453A3 (en) 2021-04-08
WO2021007453A2 (en) 2021-01-14
US20220280652A1 (en) 2022-09-08
CA3145992A1 (en) 2021-01-14
EP3997109A2 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
CN109803977B (zh) 核酸产品及其施用方法
Seto et al. Deficiency of α-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodeling
Zuris et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
Gabriel et al. Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus
BR112019009316A2 (pt) anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
BRPI0917470B8 (pt) anticorpo anti-lag-3 ou uma porção de ligação ao antígeno do mesmo, seu método de preparação, seus usos, composição, imunoconjugado, molécula de ácido nucleico isolado, vetor de expressão e método de estímulo de uma resposta de células t antígenoespecífica
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
CN109477102A (zh) 核酸产品及其施用方法
CY1123760T1 (el) Ανασυνδυασμενοι φορεις aav που εκφραζουν οστεοπροστατευτικα γονιδια, που περιλαμβανουν has2 και λουμπρικινη, χρησιμοι στην θεραπευτικη αγωγη οστεοαρθριτιδας και συναφων παθησεων των αρθρωσεων στα θηλαστικα
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
MX2020010994A (es) Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
BR112022001657A2 (pt) Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
BR112022018254A2 (pt) Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR112023001456A2 (pt) Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
BR112021017703A8 (pt) Receptores de células t wt1 de alta avidez e usos dos mesmos
BR112019005001A2 (pt) proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
Ortiz-Cordero et al. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes
BR112022000397A2 (pt) Imuno-direcionamento não viral